Published in final edited form as:

J Am Chem Soc. 2015 June 17; 137(23): 7306–7309. doi:10.1021/jacs.5b04686.

A Synthesis of Alsmaphorazine B Demonstrates the Chemical Feasibility of a New Biogenetic Hypothesis

Allen Y. Hong and Christopher D. Vanderwal*

Department of Chemistry, University of California, Irvine, 1102 Natural Sciences II, Irvine, California 92697-2025, United States

Abstract

An *N*-oxide fragmentation/hydroxylamine oxidation/intramolecular 1,3-dipolar cycloaddition cascade efficiently converted an oxidized congener of akuammicine into the complex, hexacyclic architecture of the alsmaphorazine alkaloids. This dramatic structural change shows the chemical feasibility of our novel proposal for alsmaphorazine biogenesis. Critical to these endeavors was a marked improvement in our previously reported Zincke aldehyde cycloaddition approach to indole alkaloids, which permitted the gram-scale synthesis of akuammicine. The chemoselective oxidations of akuammicine leading up to the key rearrangement also generated several biogenetically related alkaloids of the alstolucine and alpneumine families.

Graphical abstract

Inspiration from presumed biogeneses has led to compelling outcomes in numerous alkaloid syntheses.¹ In one historically fascinating example, Woodward patterned aspects of his landmark strychnine synthesis² on a hypothesis that its biosynthesis might involve an arene oxidative cleavage event.³ While this attractive idea turned out to be incorrect, his thoughts about strychnine's biogenesis were likely critical to the design of the successful approach. Here, we put forth a new biogenetic hypothesis for the origins of the hexacyclic alsmaphorazine alkaloids—one that might or might not be correct—and demonstrate how this way of thinking enabled the first synthesis of alsmaphorazine B.

© 2015 American Chemical Society

*Corresponding Author: cdv@uci.edu.

ASSOCIATED CONTENT

Supporting Information

Experimental procedures and characterization data for all new compounds, X-ray crystallographic structures, and information for **2** and **20** (CIF). The Supporting Information is available free of charge on the ACS Publications website at DOI: [10.1021/jacs.5b04686](https://doi.org/10.1021/jacs.5b04686).

The authors declare no competing financial interest.

Alsmaphorazines A and B (**1** and **2**, Figure 1) feature a stereochemically dense, highly oxidized, and cage-like hexacyclic skeleton with an endocyclic N–O bond that is rarely encountered in indole alkaloids. In their report on the isolation and structural elucidation of these compounds,⁴ the Morita group put forth a proposed biosynthesis via akuammicine-type intermediates involving multiple stepwise oxidations and rearrangements to access the alsmaphorazines. Our analysis of the structural relationship between the alsmaphorazines, which were isolated from the tree *Alstonia pneumatophora*, and other well-known alkaloids from *Alstonia* led us to propose a new biogenesis of **1** and **2**.

Our alternative biogenetic hypothesis also centered on the idea of performing multiple oxidations of akuammicine.^{5,6} Of course, 1,2-oxazolidines are retrons for application of the nitron-alkene 1,3-dipolar cycloaddition,⁷ and we viewed nitron/enone **3** (Scheme 1) as a key progenitor of the alsmaphorazine framework. This fleeting intermediate might be formed by β -elimination of a tertiary amine *N*-oxide and *in situ* hydroxylamine oxidation starting from intermediates of type **4**, one diastereoisomer of which corresponds to the enantiomeric natural products alstolucine C and alpneumine C.⁸ The requisite C19 and N4-oxidations of akuammicine (**5**) to **4** appeared straightforward, and during the course of our investigations, Andrade et al. reported just these types of transformations.⁶ⁱ Numerous syntheses of akuammicine have been reported, with Andrade's six-step synthesis of ($\pm$)-**5** currently standing as the most concise.^{6f} The directness of our previously described Zincke aldehyde-based approach to *Strychnos*-type alkaloids was also attractive.⁹ We recognized that the alsmaphorazine challenge provided an excellent opportunity for optimization and extension of our chemistry to procure the quantities of akuammicine needed to study our hypothesis for biogenesis of the alsmaphorazines.

Our synthesis of akuammicine began with reductive amination of tryptamine with *p*-anisaldehyde to give secondary amine **7** (Scheme 2), which was treated with potassium glutaconate salt **8** according to modified Marazano conditions¹⁰ (in lieu of Zincke pyridinium ring opening^{9,11}) to deliver Zincke aldehyde **9** in 93% yield from tryptamine. Notably, this improved procedure greatly simplifies the purification of the key Zincke aldehyde, requiring only trituration of the crude material. Subsequent base-mediated formal cycloaddition⁹ provided tetracyclic enal **10** in 89% yield. Numerous attempts were made at direct C17 oxidation; however, the free indoline proved to be a liability. In the end, several steps were needed to reliably change the C17 oxidation state and to refunctionalize N4; however, each of these reactions proved efficient even on multigram scales, and the intramolecular Heck reaction precursor **13** could be reliably accessed. This final ring closure, patterned on the work of Rawal,^{6e,12} MacMillan,^{6g} and Andrade,^{6f,h,i} was remarkably efficient. The nine-step sequence to akuammicine proceeded in nearly 40% overall yield and procured gram quantities of the racemic alkaloid for our alsmaphorazine studies.

For the next stage of our plan, we sought to perform selective oxidations of akuammicine to arrive at the ketone natural products of the alstolucine and alpneumine series (Scheme 3).¹³ Our efforts to engage the C19–C20 alkene with Wacker and peracid oxidations, as well as thiol-ene, oxymercuration, and hydroboration reactions, were met either with outright failure or undesired regioselectivity. Inspired by the precedent of Brown and Djerassi,¹⁴ in which

stoichiometric osmium tetroxide was used to dihydroxylate akuammicine, we evaluated catalytic variants, eventually settling on the conditions developed by Fokin and Sharpless¹⁵ owing to the relative ease of extractive removal of osmium remnants. Attempts to extend this oxidation process to an alkene ketohydroxylation by employing the conditions of DuBois¹⁶ proved unsuccessful, and only starting material and minor products of dihydroxylation were observed. We made many attempts to effect a hydride shift of the intermediate diol directly to the C19 ketone with no success. We performed the oxidation of crude diol with CrO₃ as prescribed by Brown and Djerassi,¹⁴ but only obtained 27% yield (two steps) of α -hydroxyketone **14**. Oxidation by the Dess–Martin periodinane proved sluggish depending on the batch of diol. Careful evaluation of the reaction conditions led to the identification of *t*-BuOH as a critical accelerant,¹⁷ providing product **14** in 68% yield over two steps. SmI₂ reduction of the α -ketol¹⁸ provided an inconsequential 1:1.5 mixture of alstolucine F/alpneumine E (**15**) and alstolucine B (**16**). The components can be separated by chromatography, providing the former in 33% yield and the latter in 61% yield; however, we typically use the crude mixture of ketones in subsequent operations. Exposure of the diastereomeric mixture of methyl ketones to DMDO at –78 °C led to quantitative conversion to the corresponding *N*-oxides, **17** and **18**, the latter of which is the racemate of the enantiomeric natural products alstolucine C and alpneumine C. Minimal C20 epimerization was observed during this reaction, as determined by ¹H NMR (1:1.4 dr).

The final and key stage in our plan was also the riskiest. We needed to initiate a base-mediated elimination or thermal Cope elimination to liberate an enone and a hydroxylamine (see **19**), the latter of which needed to be oxidized *in situ* to a reactive nitron for 1,3-dipolar cycloaddition. The precedent of Ciganek¹⁹ showed that it is indeed possible to execute E1_{cb} eliminations of cyclic piperidine *N*-oxides with adjacent electron-accepting groups, but the hydroxylamines thus formed readily recyclize by conjugate addition upon standing. We reasoned that the intermediate hydroxylamine might be intercepted by air oxidation²⁰ to selectively generate the desired nitron intermediate, which would participate in the intramolecular cycloaddition. With this idea in mind, we heated the mixture of *N*-oxides²¹ in toluene in the presence of DBU under an atmosphere of air. After complete consumption of starting material, we painstakingly separated the complex mixture of cycloadduct **20**, nitron isomer **21**, and amines **15** and **16** along with other unidentified side products. The structure of cycloadduct **20** was confirmed by single crystal X-ray diffraction. The formation of amines **15** and **16** might be explained by a disproportionation process²² in which the intermediate hydroxylamine **19** might shuffle oxidation states to give amines and nitrons.

On the basis of this result, we reasoned that a more strongly oxidizing atmosphere might facilitate complete oxidation to the desired nitron and mitigate the presumed disproportionation. Indeed, conducting the same reaction under an oxygen balloon led to an isolated yield of cycloadduct **19** in 49% yield over three steps along with fully substituted nitron **20** in 29% yield.

Only oxidation of the vinylogous carbamate, which was expected to be highly stereoselective by virtue of the cage-like ring system, separated **20** from alsmaphorazine B. On the basis of numerous studies toward *Vinca* alkaloids,²³ we treated the cycloadduct with *m*-CPBA in the presence of various additives; however, only decomposition was observed.

DMDO and peroxide reagents also proved ineffective. It appeared that N4 underwent competitive oxidation, and Baeyer–Villiger oxidation of the ketone might also have occurred under some conditions. Furthermore, the indolenine of alsmaphorazine B could potentially undergo oxidation, further complicating our efforts at a selective reaction. We reasoned that deprotonation of the vinylogous carbamate moiety could increase its relative reactivity and facilitate oxidation to the tertiary alcohol. Indeed, metallation of the vinylogous carbamate of **20** followed by treatment with Davis oxaziridine provided alsmaphorazine B in 82% yield. The structure of our synthetic sample was confirmed by single crystal X-ray diffraction, and the accumulated spectral data were in agreement with those reported by Morita.⁴

We have completed the first synthesis of alsmaphorazine B in 15 steps and 10.6% overall yield by recognizing its potential biosynthetic connection to akuammicine via oxidation-induced fragmentation and nitron/alkene dipolar cycloaddition. To achieve this goal, we improved and extended our Zincke aldehyde methodology to facilitate the gram-scale synthesis of akuammicine. Subsequent chemoselective oxidation of the pentacyclic framework provided several alkaloids of intermediate levels of oxidation. Although our synthesis produces racemic material, we recognize that many of the intermediate alkaloids have been isolated in both enantiomeric forms,⁸ with representatives in each series demonstrating interesting biological activities; resolutions of synthetic **15** and **18**, for example, will each yield two natural products. In our key fragmentation/oxidation/dipolar cycloaddition step, the cogeneration of the two complementary reactive functionalities for the dipolar cycloaddition is noteworthy. Our synthetic work provides a meaningful biosynthetic oxidation pathway that connects all of these *Alstonia* alkaloids and provides strong support for our biogenetic proposal that features a nitron/alkene 1,3-dipolar cycloaddition, adding to the current literature of such dipolar cycloadditions in complex alkaloid biosynthesis.^{24,25}

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

Prof. David Martin and Lucas Nguyen are acknowledged for insight and experimental advice. This work was generously supported by the NSF (CHE-1262040 to C.D.V) and an NIH-NIGMS Postdoctoral Fellowship (F32 GM103058 to A.Y.H.). We thank Profs. Larry Overman and Sergey Pronin for helpful discussions.

REFERENCES

1. For a review, see: Scholz U, Winterfeldt E. Nat. Prod. Rep. 2000; 17:349–366. [PubMed: 11014337]
2. Woodward RB, Cava MP, Ollis WD, Hunger A, Daeniker HU, Schenker K. Tetrahedron. 1963; 19:247–288.
3. Woodward RB. Nature. 1948; 162:155–156. [PubMed: 18871488]
4. Koyama K, Hirasawa Y, Nugroho AE, Hosoya T, Hoe TC, Chan K-L, Morita H. Org. Lett. 2010; 12:4188–4191. [PubMed: 20735079]

5. Isolation and structure determination of akuammicine: Millson MF, Robinson R, Thomas AF. *Experientia*. 1953; 9:89–91. [PubMed: 13068383] Edwards PN, Smith GF. *J. Chem. Soc.* 1961:152–156.
6. Syntheses of akuammicine: Angle SR, Fevig JM, Knight SD, Marquis RW Jr, Overman LE. *J. Am. Chem. Soc.* 1993; 115:3966–3976. Kuehne ME, Xu F, Brook CS. *J. Org. Chem.* 1994; 59:7803–7806. Martin SF, Clark CW, Ito M, Mortimore M. *J. Am. Chem. Soc.* 1996; 118:9804–9805. Bonjoch J, Solé D, García-Rubio S, Bosch J. *J. Am. Chem. Soc.* 1997; 119:7230–7240. He S PhD. Dissertation (Rawal). 2001 University of Chicago Chicago, IL Sirasani G, Paul T, Dougherty W Jr, Kassel S, Andrade RB. *J. Org. Chem.* 2010; 75:3529–3532. [PubMed: 20408591] Jones SB, Simmons B, Mastracchio A, MacMillan DWC. *Nature*. 2011; 475:183–188. [PubMed: 21753848] Munagala S, Sirasani G, Kokkonda P, Phadke M, Krynetskaia N, Lu P, Sharom FJ, Chaudhury S, Abdulhameed MDM, Tawa G, Wallqvist A, Martinez R, Childers W, Abou-Gharbia M, Krynetskiy E, Andrade RB. *Bioorg. Med. Chem.* 2014; 22:1148–1155. [PubMed: 24405813] Teijaro CN, Munagala S, Zhao S, Sirasani G, Kokkonda P, Malofeeva EK, Hopper-Borge E, Andrade RB. *J. Med. Chem.* 2014; 57:10383–10390. [PubMed: 25419978]
7. Confalone PN, Huie EM. *Org. React.* 1988; 36:1–174.
8. (a) Tan S-J, Low Y-Y, Choo Y-M, Abdullah Z, Etoh T, Hayashi M, Komiyama K, Kam T-S. *J. Nat. Prod.* 2010; 73:1891–1897. [PubMed: 21043460] (b) Koyama K, Hirasawa Y, Hosoya T, Hoe TC, Chan K-L, Morita H. *Bioorg. Med. Chem.* 2010; 18:4415–4421. [PubMed: 20576577]
9. (a) Martin DBC, Vanderwal CD. *J. Am. Chem. Soc.* 2009; 131:3472–3473. [PubMed: 19236094] (b) Martin DBC, Vanderwal CD. *Chem. Sci.* 2011; 2:649–651. (c) Vanderwal CD. *J. Org. Chem.* 2011; 76:9555–9567. [PubMed: 21877712] (d) Martin DBC, Nguyen LQ, Vanderwal CD. *J. Org. Chem.* 2012; 77:17–46. [PubMed: 22168233]
10. (a) Nuhant P, Raikar SB, Wypych J-C, Delpech B, Marazano C. *J. Org. Chem.* 2009; 74:9413–9421. [PubMed: 19924881] (b) Nguyen TM, Peixoto S, Ouairy C, Nguyen TD, Bénèche M, Marazano C, Michel P. *Synthesis*. 2010:103–109.
11. Zincke T, Würker W. *Liebigs Ann. Chem.* 1904; 338:107–141.
12. Rawal VH, Michoud C. *Tetrahedron Lett.* 1991; 32:1695–1698.
13. Curiously, the alstolucines and alpneumines are in opposite enantiomeric series. Also, the alsmaphorazines and alpneuimines are isolated from the same plant species and yet are in opposite enantiomeric series.
14. Gilbert B, Duarte AP, Nakagawa Y, Joule JA, Flores SE, Brissolèse JA, Campello J, Carrazzoni EP, Owellen RJ, Blossy EC, Brown KS Jr, Djerassi C. *Tetrahedron*. 1965; 21:1141–1166. [PubMed: 5879346]
15. Dupau P, Epple R, Thomas AA, Fokin VV, Sharpless KB. *Adv. Synth. Catal.* 2002; 344:421–433.
16. Fleming JJ, McReynolds MD, DuBois J. *J. Am. Chem. Soc.* 2007; 129:9964–9975. [PubMed: 17658800]
17. Dess DB, Martin JC. *J. Org. Chem.* 1983; 48:4155–4156.
18. (a) Molander GA, Hahn G. *J. Org. Chem.* 1986; 51:1135–1138. (b) White JD, Somers TC. *J. Am. Chem. Soc.* 1994; 116:9912–9920. (c) Jiang X, Wang C, Hu Y, Hu H, Covey DF. *J. Org. Chem.* 2000; 65:3555–3557. [PubMed: 10843648]
19. Ciganek E, Read JM Jr, Calabrese JC. *J. Org. Chem.* 1995; 60:5795–5802.
20. Johnson DH, Rogers MAT, Trappe G. *J. Chem. Soc.* 1956:1093–1103.
21. This mixture of ketones **15** and **16** and of *N*-oxides **17** and **18** was generally carried forward without separation. However, for characterization purposes, we have separated **15** and **16** and independently oxidized them to **17** and **18**, respectively. See the Supporting Information for details.
22. Laughlin RG. *J. Am. Chem. Soc.* 1973; 95:3295–3299.
23. (a) Hugel G, Massiot G, Lévy J, Le Men J. *Tetrahedron*. 1981; 37:1369–1375. (b) Danieli B, Lesma G, Palmisano G, Riva R. *J. Chem. Soc., Chem. Commun.* 1984:909–911. (c) Kuehne ME, Podhorez DE, Mulamba T, Bornmann WG. *J. Org. Chem.* 1987; 52:347–353. (d) Kobayashi S, Ueda T, Fukuyama T, Synlett. 2000:883–886. (e) Nemes A, Szántay C Jr, Czibula L, Greiner I. *Heterocycles*. 2007; 71:2347–2362.

24. For recent total syntheses of alkaloids employing biomimetic nitron-alkene 1,3-dipolar cycloadditions, see: Miyatake-Ondozabal H, Bannwart LM, Gademann K. Chem. Commun. 2013; 49:1921–1932. Wei H, Qiao C, Liu G, Yang Z, Li C-c. Angew. Chem. Int. Ed. 2013; 52:620–624. Ma N, Yao Y, Zhao B-X, Wang Y, Ye W-C, Jiang S. Chem. Commun. 2014; 50:9284–9287.
25. For computational studies of nitron/alkene 1,3-dipolar cycloadditions in alkaloid biosynthesis, see: Krenke EH, Patel A, Houk KN. J. Am. Chem. Soc. 2013; 135:17638–17642. [PubMed: 24195703] Painter PP, Pemberton RP, Wong BM, Ho KC, Tantillo DJ. J. Org. Chem. 2014; 79:432–435. [PubMed: 24236542]

Figure 1.
Alsmaphorazines A and B.

Scheme 1.
Proposed Biogenesis of Alsmaphorazine B

Scheme 2.

A Nine-Step Synthesis of Akuammicine Amenable to the Production of Gram Quantities

Scheme 3.

Synthesis of (±)-Alsmaphorazine B by Successive Oxidations of Akuammicine